GEN-ERIC News

The agreement, under which a commercial licence will be negotiated, sets out a codevelopment program for condoms with a VivaGel® coating. Undisclosed fees are payable to Starpharma under the co-development agreement, which also provides for the commencement of regulatory and market development activities by the two parties. SSL is the world’s largest manufacturer of condoms with approximately 30% share of the global market for branded condom sales, selling into over 100 countries around the world. Global condom retail sales in 2005 were approximately $3.2 billion, with the top four companies representing as much as 70% of the market. “We are delighted to be working with SSL, whom we believe will be an excellent codevelopment partner for VivaGel® as a condom coating,” said Starpharma’s Chief Executive Officer, Dr Jackie Fairley. “In addition to SSL’s unparalleled global commercial position and the strength of the Durex® brand, Starpharma also values the organisation’s innovative approach, and its social-marketing program.